EBAMed Raises CHF 1.2 Million to Advance Non-Invasive Therapy for Heart Arrhythmias
scroll south
The funding supports development of first integrated heart motion management system and pre-clinical testing. Discover the startup's next steps in our interview with CEO and co-founder Adriano Garonna.
The startup won training, support and 130,000 francs in Venture Kick in 2018, the same year CEO and co-founder Adriano Garonna roadshowed in Boston with Venture Leaders Life Sciences.
What is EBAMed's mission and core innovation?
Our mission is to enable access to non-invasive treatments for heart arrhythmias with protontherapy, thus addressing the limitations of today’s surgical treatments. EBAMed is developing hardware and software that expand treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
How will the 1.2-million-franc investment led by Fongit Seed Invest help achieve your vision?
This first investment round will be used to test EBAMed’s first, integrated ultrasound-based device to monitor heart motion and command the therapy machine. These pre-clinical tests are planned for 2020 in at least one protontherapy center in Europe or the United States.
You won Venture Kick in 2018. How did Venture Kick help you lay the foundation for your growth and today's achievement?
The Venture Kick program’s pitching and coaching sessions were instrumental in establishing a solid business plan and a comprehensive vision of the company’s future challenges and opportunities. In addition, the related financing helped cover the expenses for critical activities in EBAMed’s early days and increase our credibility within the local startup eco-system.
You also won your seat to Venture Leaders Life Sciences in 2018. How did Venture Leaders help you?
Venture Leaders Life Sciences was an incredible opportunity to meet experienced investors, hear their feedbacks and improve our communication. This helped us be better prepared for our first financing round. In addition, we met with fellow life science entrepreneurs in Switzerland, with whom we are still in contact and exchange valuable advice.
